Jun 07, 2023 / 01:00PM GMT
Unidentifed Participant -
Good morning, and welcome to the Jefferies 2023 Healthcare Investment Banking Conference. It's my great pleasure to introduce Brian DeSchuytner from Mersana Therapeutics.
Brian DeSchuytner - Mersana Therapeutics, Inc. - SVP & CFO
All right. Thanks so much, and thank you to Jefferies for hosting us today. Please advance the slides.
Just as a reminder, I'll be making forward-looking statements today in this presentation. Important disclosures about those statements and the risk can be found in our SEC filings available at sec.gov.
So Mersana was founded about a decade ago as an ADC company, with the recognition that ADCs were a validated modality, but one that had certain limitations from the first-generation platforms. So we set out to develop a suite of technologies that would address some of those limitations. And today, we find ourselves with three proprietary platforms: two delivering a cytotoxic and one delivering an immune stimulator.
We find ourselves with a lead asset, UpRi, on the verge of a pivotal
Mersana Therapeutics Inc at Jefferies Healthcare Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers